Goldman Sachs raises Ideaya Biosciences stock price target on trial data

Goldman Sachs raised its price target on IDEAYA Biosciences to $35 from $31 while keeping a Neutral rating, after positive Phase 2/3 data for darovasertib plus crizotinib in metastatic uveal melanoma. The trial met its primary endpoint with median progression-free survival of 6.9 months versus 3.1 months in control and a hazard ratio of 0.42; IDEAYA plans an accelerated-approval filing in 2H 2026. Goldman also lifted its probability of success to 90% from 85%, though the article still notes the stock may be slightly overvalued at current levels.

Analysis

IDYA’s re-rating is now less about “clinical optionality” and more about the market assigning a near-regulatory asset value to darovasertib. The important second-order effect is that once a program is perceived as de-risked, the stock starts trading on launch economics rather than proof-of-concept, which compresses the upside from additional data while increasing sensitivity to any FDA wording, label breadth, or trial-design ambiguity. In other words, the easy part of the rerate may already be in the stock.

The real strategic value is in the platform: positive data in one indication increases partnering leverage across the pipeline and improves the economics of future combinations. That benefits IDYA, but it also shifts negotiating power toward larger oncology partners who can demand better economics in exchange for co-development or commercialization support. AZN is the clearest external beneficiary if the collaboration expands, because it gets pipeline exposure without bearing full discovery risk, while Servier retains upside but faces rising scrutiny on whether it can defend the current standard of care in a niche market.

Consensus is likely underpricing two risks: first, accelerated approval timing can be value-negative if confirmatory readouts slip or become redundant, and second, a 90% PoS model often embeds optimistic assumptions about durability that can break in OS follow-up. The stock can continue to grind higher over months, but the asymmetry is now less favorable than it was on trial readout day. The better setup may be to own strength into catalysts, then fade any extension if the market begins capitalizing 2027 data as though it were already de-risked.

Key Decisions for Investors

• Maintain a tactical long in IDYA, but treat it as a catalyst-trading position rather than a core hold; use pullbacks toward the low-30s to add, and trim into strength above the updated target zone if no new FDA-positive signal emerges over the next 4-8 weeks.
• Consider a call spread on IDYA with a 3-9 month tenor to express upside into regulatory updates while capping premium burn; the thesis works best if the market continues to price accelerated approval as the base case, but vol should compress after the immediate data shock.
• Pair long IDYA / short a basket of slower-moving oncology small caps with late-stage melanoma or solid-tumor assets, to isolate the “de-risked asset” rerating trade while reducing beta to the broader biotech tape.
• If partnering momentum expands, look at AZN as a lower-volatility way to own the collaboration optionality; it benefits from external pipeline expansion without material balance-sheet strain, but the upside is more incremental and best expressed over a 6-12 month horizon.
• Do not chase a full-size position here: the reward-to-risk has improved for holders, but for new capital the asymmetry is now closer to fair value than bargain territory, so position sizing should reflect event-driven downside if OS data or FDA feedback disappoints.